Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients

Published:2022-06-21 Issue:6 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Leegwater E.¹²³^ORCID,Moes D. J. A. R.⁴,Bosma L. B. E.¹,Ottens T. H.⁵,van der Meer I. M.⁶,van Nieuwkoop C.⁶,Wilms E. B.¹²

Affiliation:

1. Department of Hospital Pharmacy, Haga Teaching Hospital, The Hague, The Netherlands

2. The Hague Hospital Pharmacy, The Hague, The Netherlands

3. Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands

4. Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands

5. Department of Intensive Care, Haga Teaching Hospital, The Hague, The Netherlands

6. Department of Internal Medicine, Haga Teaching Hospital, The Hague, The Netherlands

Abstract

The objective of this study was to describe the population pharmacokinetics of remdesivir and GS-441524 in hospitalized coronavirus disease 2019 (COVID-19) patients. A prospective observational pharmacokinetic study was performed in non-critically ill hospitalized COVID-19 patients with hypoxemia.

Funder

Haga Teaching Hospital

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00254-22

Reference38 articles.

1. NIH. 2021. Therapeutic management of hospitalized adults with COVID-19. NIH, Bethesda, MD. https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/.

2. Update Alert 2: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)

3. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

4. Remdesivir for the Treatment of Covid-19 — Final Report

5. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First analytical confirmation of drug-induced crystal nephropathy in felines caused by GS-441524, the active metabolite of Remdesivir;Journal of Pharmaceutical and Biomedical Analysis;2024-09

2. An in vitro study for reducing the cytotoxicity and dose dumping risk of remdesivir via entrapment in nanostructured lipid carriers;Scientific Reports;2024-08-21

3. Novel immunomodulatory properties of adenosine analogs promote their antiviral activity against SARS-CoV-2;EMBO Reports;2024-07-15

4. COVID-19 therapeutics;Clinical Microbiology Reviews;2024-06-13

5. Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19;Journal of Antimicrobial Chemotherapy;2024-05-06